Immunotech Biopharm’s EAL® Drug Application Accepted by Chinese Authorities

Immunotech Biopharm Ltd ( (HK:6978) ) has provided an update.

Immunotech Biopharm Ltd announced that the conditional new drug application for its core product candidate, EAL®, has been accepted by the Centre for Drug Evaluation of the National Medical Products Administration of China. EAL® is a multi-target cellular immunotherapy product with a decade-long track record in treating various cancers. This acceptance marks a significant step for the company in advancing its product pipeline and potentially strengthens its position in the biopharmaceutical industry, although future approvals and successful marketing are not guaranteed.

More about Immunotech Biopharm Ltd

Immunotech Biopharm Ltd is a leading cellular immunotherapy biopharmaceutical company in China, focusing on the research, development, and commercialization of T cell immunotherapy. Since its establishment in 2006, the company has specialized in cellular immunotherapy drugs for cancers and other major diseases, utilizing advanced theories in immunology, cell biology, and genetics. Its product pipeline includes non-genetically-modified and genetically-modified products, with main product candidates such as EAL®, the CAR-T cell series, and the TCR-T cell series.

YTD Price Performance: 60.43%

Average Trading Volume: 770,000

Technical Sentiment Signal: Sell

Current Market Cap: HK$1.9B

Learn more about 6978 stock on TipRanks’ Stock Analysis page.